Technical Analysis for PRLD - Prelude Therapeutics Incorporated
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 3.75% | |
| Bollinger Band Squeeze | Range Contraction | 3.75% | |
| Earnings Movers | Other | 3.75% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 3.75% | |
| Up 3 Days in a Row | Strength | 3.75% | |
| Upper Bollinger Band Touch | Strength | 3.75% | |
| Crossed Above 20 DMA | Bullish | 7.51% | |
| Bollinger Band Squeeze | Range Contraction | 7.51% | |
| Earnings Movers | Other | 7.51% | |
| BB Squeeze Started | Range Contraction | 7.51% |
| Alert | Time |
|---|---|
| 2x Volume Pace | about 3 hours ago |
| 1.5x Volume Pace | about 3 hours ago |
| Upper Bollinger Band Resistance | about 3 hours ago |
| Gap Down Partially Closed | about 3 hours ago |
| Gap Down Closed | about 3 hours ago |
Get a Trading Assistant
- Earnings date: 05/14/2024
Prelude Therapeutics Incorporated Description
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Lymphoma Blastoma Glioblastoma Protein Kinase Inhibitor Tyrosine Kinase Receptors Small Molecule Therapies Glioblastoma Multiforme Phosphoinositide 3 Kinase Inhibitor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.14 |
| 52 Week Low | 1.66 |
| Average Volume | 42,851 |
| 200-Day Moving Average | 3.59 |
| 50-Day Moving Average | 4.36 |
| 20-Day Moving Average | 3.83 |
| 10-Day Moving Average | 3.84 |
| Average True Range | 0.35 |
| RSI (14) | 48.98 |
| ADX | 19.53 |
| +DI | 18.54 |
| -DI | 17.79 |
| Chandelier Exit (Long, 3 ATRs) | 4.57 |
| Chandelier Exit (Short, 3 ATRs) | 4.48 |
| Upper Bollinger Bands | 4.14 |
| Lower Bollinger Band | 3.52 |
| Percent B (%b) | 0.77 |
| BandWidth | 16.21 |
| MACD Line | -0.15 |
| MACD Signal Line | -0.17 |
| MACD Histogram | 0.0278 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.56 | ||||
| Resistance 3 (R3) | 4.56 | 4.39 | 4.46 | ||
| Resistance 2 (R2) | 4.39 | 4.25 | 4.38 | 4.43 | |
| Resistance 1 (R1) | 4.19 | 4.16 | 4.29 | 4.19 | 4.40 |
| Pivot Point | 4.02 | 4.02 | 4.07 | 4.01 | 4.02 |
| Support 1 (S1) | 3.82 | 3.88 | 3.92 | 3.82 | 3.60 |
| Support 2 (S2) | 3.65 | 3.79 | 3.64 | 3.57 | |
| Support 3 (S3) | 3.45 | 3.65 | 3.54 | ||
| Support 4 (S4) | 3.45 |
